Commercialization of two blockbusters already started, with additional launches expected over the next years / Bayer announces genome-edited standable soy and development of herbicide tolerant trait to correspond with Icafolin, a unique crop …
Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
Not intended for U.S. and UK Media – European Society of Cardiology (ESC) Congress 2026:
Pivotal study met primary endpoints in the assessment of sensitivity and specificity for the diagnosis of cardiac amyloidosis based on visual scan interpretation / Phase III results in patients with suspected cardiac amyloidosis were presented at …
Finerenone slowed kidney function decline and reduced kidney-cardiovascular risk versus placebo in patients with hypertensive nephropathy
Not intended for U.S. and UK Media – Late breaking data presented at ESC Congress 2026:
A pre-specified subgroup analysis of the Phase III FIND-CKD study found that finerenone slowed kidney function decline compared with placebo in addition to standard of care in patients with hypertensive nephropathy, a population for whom there …
Phase 2 GenePHIT trial successfully randomized and completed enrollment of one of the largest gene therapy trials conducted in heart failure to date, with more than 170 participants randomized across 64 sites in 12 countries1 / …
Bayer submits application in Japan for expanded use of Kerendia in chronic kidney disease therapeutic area
Not intended for U.S. and UK Media
Submission supported by positive Phase III FIND-CKD results in patients with non-diabetic chronic kidney disease / In FIND-CKD, finerenone significantly delayed kidney disease progression and reduced cardiovascular-kidney events versus placebo, …
Bayer’s sevabertinib approved in Japan for patients with HER2-mutant non-small cell lung cancer
Not intended for U.S. and UK Media
First targeted therapy approved in Japan for this indication, with use across all lines of therapy, including first-line treatment / Approval is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety of …
Aflibercept 8 mg application for macular edema following retinal vein occlusion accepted for review in China
Not intended for U.S. and UK Media
China’s National Medical Products Administration (NMPA) has accepted for review the application for aflibercept 8 mg (114.3 mg/ml solution for injection) for the treatment of macular edema following retinal vein occlusion (RVO) / The filing is …
Bayer operationally on track, decisive progress on strategic priorities
Second quarter of 2026:
Group sales increase 2.2 percent (Fx & portfolio adj.) to 10.872 billion euros / EBITDA before special items rises 1.9 percent to 2.144 billion euros / Crop Science posts higher sales and substantial earnings growth / Pharmaceuticals sales at …
_
Bayer submits application for next indication of Kerendia in China
Not intended for U.S. and UK Media
Regulatory submission of new indication for patients with non-diabetic chronic kidney disease is based on positive data from the Phase III FIND-CKD study, presented at the 63rd European Renal Association (ERA) Congress 2026 and simultaneously …
New research by Economist Enterprise, supported by Bayer, highlights the potential of self-care to become a more integrated component of modern health systems / The research underscores that self-care works best when it is integrated into formal …